Home / Markets / News / Demerger buzz, semaglutide injection plans sees Natco Pharma shares jump 4%

Demerger buzz, semaglutide injection plans sees Natco Pharma shares jump 4%

Natco Pharma is a constituent of the Nifty Smallcap 100 index and has a market capitalisation exceeding ₹17,000 crore, according to exchange data.

Natco Pharma's board to mull demerger next week

2 min read Last Updated : Mar 20 2026 | 3:23 PM IST

Listen to This Article

Demerger: Shares of smallcap pharmaceutical company Natco Pharma were in focus on Friday ahead of a key board meeting scheduled next week to consider a demerger proposal.

The pharma stock opened 1 per cent higher at ₹950 on the National Stock Exchange and climbed to an intraday high of ₹972.50, up nearly 4 per cent. As of 10:45 AM, its shares were trading 2.5 per cent higher at ₹962.

Investor sentiment was buoyed after the company informed exchanges that its board will meet on March 24 to evaluate a proposed scheme of arrangement. The plan involves the demerger of its agrochemicals division into its wholly owned subsidiary, Natco Crop Health Sciences Ltd.

"The meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the 24th day of March 2026 to consider among other things, the Scheme of Arrangement for the demerger of Agrochemicals Division on a going concern basis into its Wholly Owned Subsidiary of the Company i.e., Natco Crop Health Sciences Limited," said the Hyderabad headquartered pharmaceutical company in filing. READ | BHEL rallies 5%, Tata Power hits 52-week high; what's driving power stocks?

In another related development, the drug maker has announced the launch of Semaglutide injection in India after receiving approval from the Central Drugs Standard Control Organisation (CDSCO). Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. READ ABOUT IT HERE

Also Read

Valuations favour private banks over PSBs: Kotak Institutional Equities

ITC stock heads for worst FY return in 6 years; is this buy opportunity?

Technology, Startups, Space startup, Food delivery

Happiest Minds up 11% as PE firms eye majority stake; company clarifies

MCX shares fall 5%, down 11% from 52-week high; here's what is dragging

Bulls fight back: Sensex up 1100 pts intraday, Nifty at 23,300; key reasons

Natco Pharma is a constituent of the Nifty Smallcap 100 index and has a market capitalisation exceeding ₹17,000 crore, according to exchange data. In the third quarter (Q3FY26), Natco Pharma's consolidated net profit grew by 14 per cent Y-o-Y to ₹151 crore and revenue from operations surged by 36 per cent to ₹647 crore.

The smallcap pharma stock has climbed 16 per cent over the past year and remained flat over two years. The counter has yielded a return of more than 75 per cent in the past three years.

Natco Pharma operates nine manufacturing facilities and two research and development centres in India.